

# Arielle Mendel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2266311/arielle-mendel-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13  
papers

78  
citations

5  
h-index

8  
g-index

15  
ext. papers

116  
ext. citations

2.8  
avg, IF

2.36  
L-index

#	Paper	IF	Citations
13	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	21
12	Hydroxychloroquine shortages during the COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	20
11	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 555-566	4.1	11
10	Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. <i>Rheumatology</i> , <b>2019</b> , 58, 2333-2335	3.9	8
9	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
8	Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: Data from the Toronto CanVasc cohort. <i>Joint Bone Spine</i> , <b>2020</b> , 87, 221-224	2.9	5
7	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
6	COVID-19 hospitalizations, intensive care unit stays, ventilation and death among patients with immune mediated inflammatory diseases compared to controls.. <i>Journal of Rheumatology</i> , <b>2022</b> ,	4.1	3
5	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 129, 119-124	2.2	1
4	An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, e612-e615	1.1	
3	Facteurs prédictifs d'événements cardiovasculaires mortels et non mortels dans la vascularite à ANCA : données de la cohorte Toronto CanVasc. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2021</b> , 88, 279-283	0.1	
2	Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1755-1756	4.1	
1	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 119-124	2.2	